LEADER 01758oam  2200505   450 
001 9910711803803321
005 20210503105827.0
035   $a(CKB)5470000002488049
035   $a(OCoLC)1086389949
035   $a(EXLCZ)995470000002488049
100   $a20190220d2019      ua             0
101 0 $aeng
135   $aurgn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining implementation of the Compounding Quality Act $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, second session, January 30, 2018
210  1$aWashington :$cU.S. Government Publishing Office,$d2019.
215   $a1 online resource (vi, 286 pages) $cillustrations
300   $a"Serial no. 115-96."
320   $aIncludes bibliographical references.
517   $aExamining implementation of the Compounding Quality Act 
606   $aDrugs$xDosage forms$xGovernment policy$zUnited States
606   $aPharmaceutical industry$xGovernment policy$zUnited States
606   $aDrug adulteration$zUnited States$xPrevention
608   $aLegislative hearings.$2lcgft
615  0$aDrugs$xDosage forms$xGovernment policy
615  0$aPharmaceutical industry$xGovernment policy
615  0$aDrug adulteration$xPrevention.
801  0$bGPO
801  1$bGPO
801  2$bMERUC
801  2$bTEU
801  2$bOCLCO
801  2$bNKF
801  2$bOCLCF
801  2$bOCLCO
801  2$bTXR
801  2$bOCLCO
801  2$bCOO
801  2$bGPO
906   $aBOOK
912   $a9910711803803321
996   $aExamining implementation of the Compounding Quality Act$93544452
997   $aUNINA